Key facts
- This page summarizes Chris H. Takimoto's Form 4 filing for IGM Biosciences, Inc. (IGMS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 23 Jul 2024, 20:44.
Chris H. Takimoto - 19 Jul 2024 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- IGMS
- Reported as of
- 19 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jul 2024, 20:44:20 UTC
- Prior SEC filing
- 18 Jun 2024
- Next SEC filing
- 17 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Misbah Tahir, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chris H. Takimoto filed Form 4 for IGM Biosciences, Inc. (IGMS) on 23 Jul 2024.
Change
- Previous filing in this sequence was filed on 18 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IGMS
transaction
Common Stock
Award
- Transaction value
- Shares
- +43,750
- Change %
- +46%
- Price
- Shares after
- 139,568
- Date
- 19 Jul 2024
- Ownership
- Direct
- Footnotes
- F1, F2
IGMS
transaction
Common Stock
Award
- Transaction value
- Shares
- +16,250
- Change %
- +12%
- Price
- Shares after
- 155,818
- Date
- 19 Jul 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IGMS
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -150,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 19 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $68.01
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on July 19, 2025 and one-eighth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.
Footnote F2
Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 150,000 shares of the Issuer's Common Stock and in exchange issued RSU grants of 43,750 shares and 16,250 shares.
Footnote F3
These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on January 19, 2026 and one-twelfth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.